Search

everythinglearnresearchcommunity

for

Search:↓

Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.

Birth control pills combined with bicalutamide are more effective at reducing excessive hair growth in women with PCOS than birth control pills alone.

Immunochemotherapy successfully treated neutropenia in a patient with Waldenström's macroglobulinemia.

A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.

Vemurafenib causes skin side effects similar to RASopathies, requiring regular skin checks and UVA protection.

Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.

Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.

Baricitinib may effectively treat lichen planopilaris.

BRAF inhibitors for melanoma often cause skin side effects, but they can be managed with proper care.

Baricitinib is effective and safe for treating severe alopecia areata, promoting significant hair regrowth.

Dupilumab can both trigger and treat alopecia areata, often leading to hair regrowth.

Bicalutamide can reduce female pattern hair loss, especially in those with certain conditions, but has limited effects on other hair loss types.

A man was diagnosed with a rare form of lupus after showing unique skin symptoms that responded well to treatment.

Skin-resident memory T cells may contribute to chronic alopecia areata and baricitinib could be a potential treatment.

Ritlecitinib is more effective and cheaper than baricitinib for treating severe alopecia areata.

Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.

Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.

Baricitinib effectively treats severe alopecia for up to 104 weeks.

BLZ-100 is safe for use in skin cancer surgery and may help identify cancerous tissue.

Baricitinib helps keep hair, eyebrows, and eyelashes regrown for 3 years in most people with severe hair loss.

Oral ritlecitinib and baricitinib are promising treatments for severe alopecia areata due to their balance of effectiveness and safety.

Anti-TNF therapy can cause hair loss and skin issues.

Mimosine dipeptides are promising for treating hyperpigmentation and inflammation.

Composite biomaterials can precisely control immune responses for better disease treatment.

Early use of infliximab in severe pediatric Crohn's disease can lead to significant improvement and remission.

Targeted immunological therapies offer safer and more effective treatments for skin conditions like eczema and psoriasis.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

RUM-loaded SLN shows promise for treating acne and hair loss topically.

Upadacitinib effectively treats pyoderma gangrenosum.